Abou-Alfa, G. K., Chan, S. L., Goyal, L., Khaled, N. B., Kudo, M., Lamarca, A., Merle, P., Rimassa, L., Yoo, C., Zhong, Y., Qu, X., Xiang, J., Zhou, J. (2026). ARTEMIDE-HCC01: A phase 3, randomized, open-label, sponsor-blinded, multicentre, global study of rilvegostomig in combination with bevacizumab with or without tremelimumab as first-line (1L) treatment for unresectable hepatocellular carcinoma (uHCC).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.2_suppl.tps612